Recruiting
Phase 3

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Code:

NCT04892173

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Aged

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

JNJ-90301900 (NBTXR3)

Cetuximab

Radiation Therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information